CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 6 incoming connections
- ScaleRevenue is $3.04B, above the global median of $548.88M
- PositionP/E ratio is 7.78×, lower than 95% of its Pharmaceutical Retailers peers (median 18.97×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
6.53%
Annual Rate
BRL 0.26Paid annual
Payout Ratio
51.0%Sustainable
Payback Period
13.1 yr
Last Ex-Dividend
Dec 26, 2025
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.90BBRL563.93M · vs all stocks (USD)
Trailing P/E
7.78xvs Pharmaceutical Retailers peers
Revenue (TTM)
15.64BBRL3.04B · vs all stocks (USD)
Profit Margin
2.10%vs Pharmaceutical Retailers peers
Beta
0.0350xvs all stocks
52-Week Change
9.78%vs all stocks
Market Capitalization
2.90BBRL563.93M · vs all stocks (USD)
Enterprise Value
6.19BBRL1.20B · vs all stocks (USD)
Trailing P/E
7.78xvs Pharmaceutical Retailers peers
Forward P/E
5.67xvs Pharmaceutical Retailers peers
PEG Ratio
0.6658xPrice to Sales (TTM)
0.1788xvs Pharmaceutical Retailers peers
Price to Book (MRQ)
0.8196xvs Pharmaceutical Retailers peers
Enterprise to Revenue
0.3960xvs Pharmaceutical Retailers peers
Enterprise to EBITDA
6.58xvs Pharmaceutical Retailers peers
Gross Margin
33.30%vs Pharmaceutical Retailers peers
Profit Margin
2.10%vs Pharmaceutical Retailers peers
Operating Margin
6.76%vs Pharmaceutical Retailers peers
Return on Assets (TTM)
6.26%vs Pharmaceutical Retailers peers
Return on Equity (TTM)
10.59%vs Pharmaceutical Retailers peers
Revenue (TTM)
15.64BBRL3.04B · vs all stocks (USD)
Revenue per Share (TTM)
23.35BRLUpdated Sep 23, 2026Quarterly Revenue Growth
8.00%vs Pharmaceutical Retailers peers
Gross Profit (TTM)
5.05BBRL983.11M · vs all stocks (USD)
EBITDA (TTM)
1.23BBRL239.50M · vs all stocks (USD)
Net Income (TTM)
328.41MBRL63.93M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
41.60%vs Pharmaceutical Retailers peers
Operating Cash Flow (TTM)
342.16MBRL66.60M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-80.00MBRL-15.57M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.2565BRLUpdated Sep 23, 2026Trailing Annual Dividend Yield
6.53%vs all stocks
Payout Ratio
51.05%vs Pharmaceutical Retailers peers
Minority Interest (Equity)
8.21MBRLFY2025 · Dec 31, 2025Revenue
14.91BBRLFY2025 · Dec 31, 2025Cost of Goods Sold
10.14BBRLFY2025 · Dec 31, 2025Gross Profit
4.76BBRLFY2025 · Dec 31, 2025Operating Income
853.83MBRL166.21M · vs all stocks (USD)
Pre-tax Income
174.97MBRLFY2025 · Dec 31, 2025Income Tax Expense
-85.96MBRLFY2025 · Dec 31, 2025Net Income
260.93MBRLFY2025 · Dec 31, 2025EBIT
679.18MBRLFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.23BBRLFY2025 · Dec 31, 2025Selling, General & Administrative
3.91BBRLFY2025 · Dec 31, 2025Other Operating Expenses
3.22MBRLFY2025 · Dec 31, 2025Non-operating Interest Income
62.61MBRLFY2025 · Dec 31, 2025Non-operating Interest Expense
504.21MBRLFY2025 · Dec 31, 2025Net Income from Continuing Operations
260.93MBRLFY2025 · Dec 31, 2025Minority Interests (P&L)
-648.00KBRLFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00BRLFY2025 · Dec 31, 2025Operating Cash Flow
-296.61MBRLFY2025 · Dec 31, 2025Free Cash Flow
-510.91MBRLFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
185.76MBRLFY2025 · Dec 31, 2025Starting Profit (CF Statement)
260.93MBRLFY2025 · Dec 31, 2025Other Non-cash Items
448.00MBRLFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-617.49MBRLFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-388.05MBRLFY2025 · Dec 31, 2025Capital Expenditures
-214.30MBRLFY2025 · Dec 31, 2025Net Intangibles (CF)
-47.13MBRLFY2025 · Dec 31, 2025Sale of Investments
195.00KBRLFY2025 · Dec 31, 2025Net Investing Cash Flow
-214.10MBRLFY2025 · Dec 31, 2025Long-term Debt Issuance
1.27BBRLFY2025 · Dec 31, 2025Long-term Debt Payments
-931.63MBRLFY2025 · Dec 31, 2025Common Stock Repurchase
-16.49MBRLFY2025 · Dec 31, 2025Common Dividends Paid
-176.41MBRLFY2025 · Dec 31, 2025Net Financing Cash Flow
406.75MBRLFY2025 · Dec 31, 2025Shares Outstanding
720.15MSharesUpdated Sep 23, 2026Float Shares
168.69MSharesUpdated Sep 23, 2026% Held by Insiders
57.39%vs all stocks
% Held by Institutions
30.85%vs all stocks
Total Cash (MRQ)
111.18MBRL21.64M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1540BRLUpdated Sep 23, 2026Total Debt (MRQ)
3.49BBRL678.81M · vs all stocks (USD)
Total Debt to Equity (MRQ)
1.02xvs Pharmaceutical Retailers peers
Current Ratio (MRQ)
1.78xvs Pharmaceutical Retailers peers
Book Value per Share (MRQ)
4.75BRLUpdated Sep 23, 2026Total Assets
9.92BBRL1.93B · vs all stocks (USD)
Total Current Assets
5.69BBRLFY2025 · Dec 31, 2025Total Liabilities
6.83BBRLFY2025 · Dec 31, 2025Total Non-current Assets
4.23BBRLFY2025 · Dec 31, 2025Total Non-current Liabilities
3.25BBRLFY2025 · Dec 31, 2025Total Current Liabilities
3.58BBRLFY2025 · Dec 31, 2025Cash
53.84MBRLFY2025 · Dec 31, 2025Cash Equivalents
131.92MBRLFY2025 · Dec 31, 2025Cash & Cash Equivalents
185.76MBRLFY2025 · Dec 31, 2025Other Short-term Investments
37.00KBRLFY2025 · Dec 31, 2025Accounts Receivable
1.23BBRLFY2025 · Dec 31, 2025Inventory
3.70BBRLFY2025 · Dec 31, 2025Accounts Payable
2.61BBRLFY2025 · Dec 31, 2025Short-term Debt
478.06MBRLFY2025 · Dec 31, 2025Long-term Debt
3.21BBRLFY2025 · Dec 31, 2025Other Non-current Liabilities
12.98MBRLFY2025 · Dec 31, 2025Common Stock (Book)
1.97BBRLFY2025 · Dec 31, 2025Retained Earnings
0.00BRLFY2025 · Dec 31, 2025Total Shareholders' Equity
3.09BBRL602.16M · vs all stocks (USD)
52-Week Low
3.09BRLUpdated Sep 23, 202652-Week High
7.62BRLUpdated Sep 23, 202652-Week Change
9.78%vs all stocks
Beta
0.0350xvs all stocks
50-Day MA
3.49BRLUpdated Sep 23, 2026200-Day MA
5.08BRLUpdated Sep 23, 2026Avg 10-Day Volume
6.46MSharesUpdated Sep 23, 2026Avg 30-Day Volume
4.75MSharesUpdated Sep 23, 2026Diluted EPS (TTM)
0.5000BRLUpdated Sep 23, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
High Current Ratio With Elevated Payables and Inventory Shares
Current assets cover its bills, though much of that is inventory and much is owed out.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
P/E ratio is 7.78×, lower than 95% of its Pharmaceutical Retailers peers (median 18.97×)Notable
P/E ratio: 7.78Industry median: 18.97Industry P5: 11.36Peers compared: 21.00
Financial Health
Altman Z-Score 2.24: grey zoneSignificant
Altman Z-Score: 2.24
Supply Chain
Midstream position: 5 outgoing, 6 incoming connectionsNotable
Outgoing: 5.00Incoming: 6.00
High connectivity hub: 11 industry connectionsNotable
Total Connections: 11.00
Scale
Revenue is $3.04B, above the global median of $548.88MNotable
Revenue (USD): 3,043,990,748.017Global Median: 548,883,780.48
Companies that share the same coordination system — how they create, deliver, or capture value.
Delek Automotive Systems Ltd.
Tier 1FlowUnit ReplicationInterfaceRisk
Pharmacy Chain 36.6 PJSC
Tier 1FlowUnit ReplicationInterfaceProduction
Haoyun Technologies Co., Ltd.
Tier 1FlowUnit ReplicationProductionRule
Daikokutenbussan Co., Ltd.
Tier 1FlowUnit ReplicationProductionInterface
SMCP S.A.
Tier 1FlowUnit ReplicationRiskInterface
Shanghai Yimin Commerce Development Co., Ltd.
Tier 1FlowUnit ReplicationInterfaceAttention
Alpen Co. Ltd.
Tier 1FlowUnit ReplicationInterfaceProduction
Erajaya Swasembada Tbk.
Tier 1FlowUnit ReplicationInterfaceRisk
Cachet Pharmaceutical Co., Ltd.
Tier 1FlowUnit ReplicationProductionInterface
Jm Holdings Co. Ltd.
Tier 1FlowUnit ReplicationInterfaceProduction
Companies that share active interpretations — structural patterns currently present in both stocks.
China Haisum Engineering Co., Ltd.
1 interpretationMulti-Year Revenue, Profit, And Income Growth
Sumber Alfaria Trijaya Tbk
1 interpretationMulti-Year Revenue, Profit, And Income Growth
Taihan Electric Wire Co., Ltd.
1 interpretationMulti-Year Revenue, Profit, And Income Growth